Quantum dots as a platform for nanoparticle drug delivery vehicle design

Advanced Drug Delivery Reviews

Volumn 65, Issue 5, 2013, Pages 703-718

  Probst, Christine E ^a   Zrazhevskiy, Pavel ^a   Bagalkot, Vaishali ^a   Gao, Xiaohu ^a  

^a University of Washington   (United States)

Author keywords

Drug delivery vehicle; Fluorescence imaging; Nanocarrier; Nanomedicine; Nanoparticle; Quantum dot; Traceable drug delivery

Indexed keywords

BIOCOMPATIBILITY; ENZYME INHIBITION; FLUORESCENCE IMAGING; MAGNETIC LEVITATION VEHICLES; MEDICAL NANOTECHNOLOGY; NANOCRYSTALS; NANOMAGNETICS; NANOPARTICLES; OPTICAL PROPERTIES; SEMICONDUCTOR QUANTUM DOTS; SURFACE CHEMISTRY; TARGETED DRUG DELIVERY; TOXICITY;

CONTROLLED DRUG RELEASE; DRUG DELIVERY APPLICATIONS; DRUG DELIVERY VEHICLES; MAGNETIC NANO-PARTICLES; NANOCARRIERS; NANOPARTICLE PROPERTIES; OVERALL CHARACTERISTICS; SYSTEMATIC EVALUATION;

CONTROLLED DRUG DELIVERY;

ANTIGEN; CONTRAST MEDIUM; DNA; DRUG CARRIER; GOLD NANOPARTICLE; MAGNETIC NANOPARTICLE; NANOPARTICLE; QUANTUM DOT; SMALL INTERFERING RNA;

BIOCOMPATIBILITY; CONTROLLED DRUG RELEASE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG TARGETING; DRUG TOXICITY; DRUG UPTAKE; HUMAN; IN VIVO STUDY; MAGNETO TRANSFECTION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PARTICLE SIZE; PHOTOTHERAPY; PHOTOTHERMAL THERAPY; PRIORITY JOURNAL; REVIEW; SENSITIVITY ANALYSIS; SURFACE PROPERTY;

EID: 84878374122     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2012.09.036     Document Type: Review

References (180)

1. Chubin D.E., Studer K.E. The politics of cancer. Theory Soc. 1978, 6(1):55-74.
2. Cutler D.M. Are we finally winning the war on cancer?. J. Econ. Perspect. 2008, 22(4):3-26.
3. Leaf C. Why we're losing the war on cancer (and how to win it). Fortune 2004, 149(6):76-82. (84-6, 88 passim).
4. Sporn M.B. The war on cancer. Lancet 1996, 347(9012):1377-1381.
5. Siegel R., et al. Cancer statistics, 2011. CA Cancer J. Clin. 2011, 61(4):212-236.
6. DeVita V.T., Chu E. A history of cancer chemotherapy. Cancer Res. 2008, 68(21):8643-8653.
7. Baclesse F. Roentgen therapy as the sole method of treatment of cancer of the breast. Am. J. Roentgenol. Radium Ther. 1949, 62(3):311-319.
8. Hanahan D., Weinberg Robert A. Hallmarks of cancer: the next generation. Cell 2011, 144(5):646-674.
9. Sumer B., Gao J. Theranostic nanomedicine for cancer. Nanomedicine 2008, 3(2):137-140.
10. Marusyk A., Polyak K. Tumor heterogeneity: causes and consequences. Biochim. Biophys. Acta, Rev. Cancer 2009, 1805(1):105-117.
11. Jin Y., Gao X. Plasmonic fluorescent quantum dots. Nat. Nanotechnol. 2009, 4(9):571-576.
12. Wang A.Z., Langer R., Farokhzad O.C. Nanoparticle delivery of cancer drugs. Annu. Rev. Med. 2011, 63:185-198.
13. Jain R.K., Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 2010, 7(11):653-664.
14. Bharali D.J., Mousa S.A. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise. Pharmacol. Ther. 2011, 128(2):324-335.
15. Delehanty J.B., et al. Quantum dots: a powerful tool for understanding the intricacies of nanoparticle-mediated drug delivery. Expert Opin. Drug Deliv. 2009, 6(10):1091-1112.
16. Qi L., Gao X.H. Emerging application of quantum dots for drug delivery and therapy. Expert Opin. Drug Deliv. 2008, 5(3):263-267.
17. Zrazhevskiy P., Sena M., Gao X. Designing multifunctional quantum dots for bioimaging, detection, and drug delivery. Chem. Soc. Rev. 2010, 39(11):4326-4354.
18. Derfus A.M., Chan W.C.W., Bhatia S.N. Probing the cytotoxicity of semiconductor quantum dots. Nano Lett. 2004, 4(1):11-18.
19. Su Y., et al. The cytotoxicity of cadmium based, aqueous phase - synthesized, quantum dots and its modulation by surface coating. Biomaterials 2009, 30(1):19-25.
20. Cho S.J., et al. Long-term exposure to CdTe quantum dots causes functional impairments in live cells. Langmuir 2007, 23(4):1974-1980.
21. Hauck T.S., et al. In vivo quantum-dot toxicity assessment. Small 2010, 6(1):138-144.
22. Ye L., et al. A pilot study in non-human primates shows no adverse response to intravenous injection of quantum dots. Nat. Nanotechnol. 2012, 7(7):453-458.
23. Barreto J.A., et al. Nanomaterials: applications in cancer imaging and therapy. Adv. Mater. 2011, 23(12):H18-H40.
24. Jin S., Ye K. Nanoparticle-mediated drug delivery and gene therapy. Biotechnol. Prog. 2007, 23(1):32-41.
25. Choi H.S., et al. Renal clearance of quantum dots. Nat. Biotechnol. 2007, 25(10):1165-1170.
26. Choi H.S., et al. Design considerations for tumour-targeted nanoparticles. Nat. Nanotechnol. 2010, 5(1):42-47.
27. Gerion D., et al. Synthesis and properties of biocompatible water-soluble silica-coated CdSe/ZnS semiconductor quantum dots. J. Phys. Chem. B 2001, 105(37):8861-8871.
28. Hu X., Zrazhevskiy P., Gao X. Encapsulation of single quantum dots with mesoporous silica. Ann. Biomed. Eng. 2009, 37(10):1960-1966.
29. Popović Z., et al. A Nanoparticle Size Series for In Vivo Fluorescence Imaging. Angew. Chem. Int. Ed. 2010, 122(46):8831-8834.
30. Obata Y., Tajima S., Takeoka S. Evaluation of pH-responsive liposomes containing amino acid-based zwitterionic lipids for improving intracellular drug delivery in vitro and in vivo. J. Control. Release 2010, 142(2):267-276.
31. Katagiri K., et al. Magnetoresponsive on-demand release of hybrid liposomes formed from Fe3O4 nanoparticles and thermosensitive block copolymers. Small 2011, 7(12):1683-1689.
32. Immordino M.L., Dosio F., Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomed. 2006, 1(3):297-315.
33. Weng K.C., et al. Targeted tumor cell internalization and imaging of multifunctional quantum dot-conjugated immunoliposomes in vitro and in vivo. Nano Lett. 2008, 8(9):2851-2857.
34. Al-Jamal W.T., et al. Functionalized-quantum-dot-liposome hybrids as multimodal nanoparticles for cancer. Small 2008, 4(9):1406-1415.
35. Al-Jamal W.T., et al. Lipid-quantum dot bilayer vesicles enhance tumor cell uptake and retention in vitro and in vivo. ACS Nano 2008, 2(3):408-418.
36. Al-Jamal K.T., et al. Tumor targeting of functionalized quantum dot-liposome hybrids by intravenous administration. Mol. Pharm. 2009, 6(2):520-530.
37. Sigot V., Arndt-Jovin D.J., Jovin T.M. Targeted cellular delivery of quantum dots loaded on and in biotinylated liposomes. Bioconjug. Chem. 2010, 21(8):1465-1472.
38. Kim B.Y., et al. Biodegradable quantum dot nanocomposites enable live cell labeling and imaging of cytoplasmic targets. Nano Lett. 2008, 8(11):3887-3892.
39. Yang C.H., et al. Microfluidic assisted synthesis of multi-functional polycaprolactone microcapsules: incorporation of CdTe quantum dots, Fe3O4 superparamagnetic nanoparticles and tamoxifen anticancer drugs. Lab Chip 2009, 9(7):961-965.
40. Chen H.H., et al. Quantitative comparison of intracellular unpacking kinetics of polyplexes by a model constructed from quantum dot-FRET. Mol. Ther. 2008, 16(2):324-332.
41. Tan W.B., Jiang S., Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 2007, 28(8):1565-1571.
42. Wu Y., et al. Uptake and intracellular fate of multifunctional nanoparticles: a comparison between lipoplexes and polyplexes via quantum dot mediated Forster resonance energy transfer. Mol. Pharm. 2011, 8(5):1662-1668.
43. Zintchenko A., et al. Drug nanocarriers labeled with near-infrared-emitting quantum dots (quantoplexes): imaging fast dynamics of distribution in living animals. Mol. Ther. 2009, 17(11):1849-1856.
44. Hobbs S.K., et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl. Acad. Sci. U. S. A. 1998, 95(8):4607-4612.
45. Jain R.K. Transport of molecules, particles, and cells in solid tumors. Annu. Rev. Biomed. Eng. 1999, 1:241-263.
46. Jain R.K. Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function. J. Control. Release 2001, 74(1-3):7-25.
47. Wong C., et al. Multistage nanoparticle delivery system for deep penetration into tumor tissue. Proc. Natl. Acad. Sci. 2010, 108(6):2426-2431.
48. Chan W.C., Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 1998, 281(5385):2016-2018.
49. Law W.C., et al. Aqueous-phase synthesis of highly luminescent CdTe/ZnTe Core/shell quantum dots optimized for targeted bioimaging. Small 2009, 5(11):1302-1310.
50. Sukhanova A., et al. Biocompatible fluorescent nanocrystals for immunolabeling of membrane proteins and cells. Anal. Biochem. 2004, 324(1):60-67.
51. Jiang W., et al. Design and characterization of lysine cross-linked mereapto-acid biocompatible quantum dots. Chem. Mater. 2006, 18(4):872-878.
52. Susumu K., et al. Multifunctional compact zwitterionic ligands for preparing robust biocompatible semiconductor quantum dots and gold nanoparticles. J. Am. Chem. Soc. 2011, 133(24):9480-9496.
53. Liu W., et al. Compact biocompatible quantum dots functionalized for cellular imaging. J. Am. Chem. Soc. 2008, 130(4):1274-1284.
54. Smith A.M., Nie S. Minimizing the hydrodynamic size of quantum dots with multifunctional multidentate polymer ligands. J. Am. Chem. Soc. 2008, 130(34):11278-11279.
55. Liu W., et al. Compact biocompatible quantum dots via RAFT-mediated synthesis of imidazole-based random copolymer ligand. J. Am. Chem. Soc. 2010, 132(2):472-483.
56. Gao J., et al. A novel clinically translatable fluorescent nanoparticle for targeted molecular imaging of tumors in living subjects. Nano Lett. 2012, 12(1):281-286.
57. Medintz I.L., et al. Proteolytic activity monitored by fluorescence resonance energy transfer through quantum-dot-peptide conjugates. Nat. Mater. 2006, 5(7):581-589.
58. Medintz I.L., et al. Self-assembled nanoscale biosensors based on quantum dot FRET donors. Nat. Mater. 2003, 2(9):630-638.
59. Delehanty J.B., et al. Self-assembled quantum dot-peptide bioconjugates for selective intracellular delivery. Bioconjug. Chem. 2006, 17(4):920-927.
60. Prasuhn D.E., et al. Combining chemoselective ligation with polyhistidine-driven self-assembly for the modular display of biomolecules on quantum dots. ACS Nano 2010, 4(1):267-278.
61. Mei B.C., et al. Polyethylene glycol-based bidentate ligands to enhance quantum dot and gold nanoparticle stability in biological media. Nat. Protoc. 2009, 4(3):412-423.
62. Bruchez M., et al. Semiconductor nanocrystals as fluorescent biological labels. Science 1998, 281(5385):2013-2016.
63. van Schooneveld M.M., et al. Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation. Nano Lett. 2008, 8(8):2517-2525.
64. Murray C.B., Norris D.J., Bawendi M.G. Synthesis and characterization of nearly monodisperse Cde (E = S, Se, Te) semiconductor nanocrystallites. J. Am. Chem. Soc. 1993, 115(19):8706-8715.
65. Peng Z.A., Peng X.G. Formation of high-quality CdTe, CdSe, and CdS nanocrystals using CdO as precursor. J. Am. Chem. Soc. 2001, 123(1):183-184.
66. Peng Z.A., Peng X.G. Nearly monodisperse and shape-controlled CdSe nanocrystals via alternative routes: nucleation and growth. J. Am. Chem. Soc. 2002, 124(13):3343-3353.
67. Qu L., Peng X. Control of photoluminescence properties of CdSe nanocrystals in growth. J. Am. Chem. Soc. 2002, 124(9):2049-2055.
68. Talapin D.V., et al. Highly luminescent monodisperse CdSe and CdSe/ZnS nanocrystals synthesized in a hexadecylamine-trioctylphosphine oxide-trioctylphospine mixture. Nano Lett. 2001, 1(4):207-211.
69. Pellegrino T., et al. Hydrophobic nanocrystals coated with an amphiphilic polymer shell: a general route to water soluble nanocrystals. Nano Lett. 2004, 4(4):703-707.
70. Geidel C., et al. A general synthetic approach for obtaining cationic and anionic inorganic nanoparticles via encapsulation in amphiphilic copolymers. Small 2011, 7(20):2929-2934.
71. Wu X., et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat. Biotechnol. 2003, 21(1):41-46.
72. Dubertret B., et al. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science 2002, 298(5599):1759-1762.
73. Jennings T.L., et al. Reactive semiconductor nanocrystals for chemoselective biolabeling and multiplexed analysis. ACS Nano 2011, 5(7):5579-5593.
74. Barat B., et al. Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection. Bioconjug. Chem. 2009, 20(8):1474-1481.
75. Xing Y., et al. Bioconjugated quantum dots for multiplexed and quantitative immunohistochemistry. Nat. Protoc. 2007, 2(5):1152-1165.
76. Goldman E.R., et al. Avidin: a natural bridge for quantum dot-antibody conjugates. J. Am. Chem. Soc. 2002, 124(22):6378-6382.
77. Mattoussi H., et al. Self-assembly of CdSe-ZnS quantum dot bioconjugates using an engineered recombinant protein. J. Am. Chem. Soc. 2000, 122(49):12142-12150.
78. Alivisatos A.P. Semiconductor clusters, nanocrystals, and quantum dots. Science 1996, 271(5251):933-937.
79. Medintz I.L., et al. Quantum dot bioconjugates for imaging, labelling and sensing. Nat. Mater. 2005, 4(6):435-446.
80. Alivisatos A.P. Perspectives on the physical chemistry of semiconductor nanocrystals. J. Phys. Chem. 1996, 100(31):13226-13239.
81. Chan W.C., et al. Luminescent quantum dots for multiplexed biological detection and imaging. Curr. Opin. Biotechnol. 2002, 13(1):40-46.
82. Kobayashi H., et al. Simultaneous multicolor imaging of five different lymphatic basins using quantum dots. Nano Lett. 2007, 7(6):1711-1716.
83. Delehanty J.B., et al. Spatiotemporal multicolor labeling of individual cells using peptide-functionalized quantum dots and mixed delivery techniques. J. Am. Chem. Soc. 2011, 133(27):10482-10489.
84. Gao X., Nie S. Molecular profiling of single cells and tissue specimens with quantum dots. Trends Biotechnol. 2003, 21(9):371-373.
85. Tokumasu F., Dvorak J. Development and application of quantum dots for immunocytochemistry of human erythrocytes. J. Microsc. 2003, 211(Pt 3):256-261.
86. Dahan M., et al. Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking. Science 2003, 302(5644):442-445.
87. Heine M., et al. Surface mobility of postsynaptic AMPARs tunes synaptic transmission. Science 2008, 320(5873):201-205.
88. Courty S., et al. Tracking individual kinesin motors in living cells using single quantum-dot imaging. Nano Lett. 2006, 6(7):1491-1495.
89. Nitzsche B., Ruhnow F., Diez S. Quantum-dot-assisted characterization of microtubule rotations during cargo transport. Nat. Nanotechnol. 2008, 3(9):552-556.
90. Jaiswal J.K., et al. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat. Biotechnol. 2003, 21(1):47-51.
91. Cui B., et al. One at a time, live tracking of NGF axonal transport using quantum dots. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(34):13666-13671.
92. Lidke D.S., et al. Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat. Biotechnol. 2004, 22(2):198-203.
93. He K., et al. Intercellular transportation of quantum dots mediated by membrane nanotubes. ACS Nano 2010, 4(6):3015-3022.
94. Joo K.I., et al. Enhanced real-time monitoring of adeno-associated virus trafficking by virus-quantum dot conjugates. ACS Nano 2011, 5(5):3523-3535.
95. Yan R., et al. Nanowire-based single-cell endoscopy. Nat. Nanotechnol. 2012, 7(3):191-196.
96. Klostranec J.M., Chan W.C.W. Quantum dots in biological and biomedical research: recent progress and present challenges. Adv. Mater. 2006, 18(15):1953-1964.
97. Gao X., et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 2004, 22(8):969-976.
98. Frangioni J.V. In vivo near-infrared fluorescence imaging. Curr. Opin. Chem. Biol. 2003, 7(5):626-634.
99. Lim Y.T., et al. Selection of quantum dot wavelengths for biomedical assays and imaging. Mol. Imaging 2003, 2(1):50-64.
100. Allen P.M., et al. InAs(ZnCdS) quantum dots optimized for biological imaging in the near-infrared. J. Am. Chem. Soc. 2010, 132(2):470-471.
101. He Y., et al. Water-dispersed near-infrared-emitting quantum dots of ultrasmall sizes for in vitro and in vivo imaging. Angew. Chem. Int. Ed. Engl. 2011, 50(25):5695-5698.
102. Hu D., et al. A fast synthesis of near-infrared emitting CdTe/CdSe quantum dots with small hydrodynamic diameter for in vivo imaging probes. Nanoscale 2011, 3(11):4724-4732.
103. Clapp A.R., et al. Fluorescence resonance energy transfer between quantum dot donors and dye-labeled protein acceptors. J. Am. Chem. Soc. 2004, 126(1):301-310.
104. Medintz I.L., Mattoussi H. Quantum dot-based resonance energy transfer and its growing application in biology. Phys. Chem. Chem. Phys. 2009, 11(1):17-45.
105. Medintz I.L., et al. Quantum-dot/dopamine bioconjugates function as redox coupled assemblies for in vitro and intracellular pH sensing. Nat. Mater. 2010, 9(8):676-684.
106. Ho Y.P., et al. Evaluating the intracellular stability and unpacking of DNA nanocomplexes by quantum dots-FRET. J. Control. Release 2006, 116(1):83-89.
107. Lee G., Chrisey L., Colton R. Direct measurement of the forces between complementary strands of DNA. Science 1994, 266(5186):771-773.
108. Lee H., Kim I.K., Park T.G. Intracellular trafficking and unpacking of siRNA/quantum dot-PEI complexes modified with and without cell penetrating peptide: confocal and flow cytometric FRET analysis. Bioconjug. Chem. 2010, 21(2):289-295.
109. Qi L., Gao X. Quantum dot-amphipol nanocomplex for intracellular delivery and real-time imaging of siRNA. ACS Nano 2008, 2(7):1403-1410.
110. Giepmans B.N., et al. Correlated light and electron microscopic imaging of multiple endogenous proteins using Quantum dots. Nat. Methods 2005, 2(10):743-749.
111. Nisman R., et al. Application of quantum dots as probes for correlative fluorescence, conventional, and energy-filtered transmission electron microscopy. J. Histochem. Cytochem. 2004, 52(1):13-18.
112. Chen F., Gerion D. Fluorescent CdSe/ZnS Nanocrystal-Peptide Conjugates for Long-term, Nontoxic Imaging and Nuclear Targeting in Living Cells. Nano Lett. 2004, 4(10):1827-1832.
113. Derfus A.M., Chan W.C.W., Bhatia S.N. Intracellular delivery of quantum dots for live cell labeling and organelle tracking. Adv. Mater. 2004, 16(12):961-966.
114. Yum K., et al. Mechanochemical delivery and dynamic tracking of fluorescent quantum dots in the cytoplasm and nucleus of living cells. Nano Lett. 2009, 9(5):2193-2198.
115. Park S., et al. Carbon nanosyringe array as a platform for intracellular delivery. Nano Lett. 2009, 9(4):1325-1329.
116. Chithrani B.D., Ghazani A.A., Chan W.C. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells. Nano Lett. 2006, 6(4):662-668.
117. He C., et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials 2010, 31(13):3657-3666.
118. Rejman J., et al. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J. 2004, 377(Pt 1):159-169.
119. Jiang W., et al. Nanoparticle-mediated cellular response is size-dependent. Nat. Nanotechnol. 2008, 3(3):145-150.
120. Lundqvist M., et al. Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(38):14265-14270.
121. Walczyk D., et al. What the cell 'sees' in bionanoscience. J. Am. Chem. Soc. 2010, 132(16):5761-5768.
122. Kairdolf B.A., et al. Minimizing nonspecific cellular binding of quantum dots with hydroxyl-derivatized surface coatings. Anal. Chem. 2008, 80(8):3029-3034.
123. Kim J.A., et al. Role of cell cycle on the cellular uptake and dilution of nanoparticles in a cell population. Nat. Nanotechnol. 2011, 7(1):62-68.
124. Barua S., Rege K. Cancer-cell-phenotype-dependent differential intracellular trafficking of unconjugated quantum dots. Small 2009, 5(3):370-376.
125. Al-Hajaj N.A., et al. Short ligands affect modes of QD uptake and elimination in human cells. ACS Nano 2011, 5(6):4909-4918.
126. Zhang L.W., Monteiro-Riviere N.A. Mechanisms of quantum dot nanoparticle cellular uptake. Toxicol. Sci. 2009, 110(1):138-155.
127. Jiang X., et al. Endo- and exocytosis of zwitterionic quantum dot nanoparticles by live HeLa cells. ACS Nano 2010, 4(11):6787-6797.
128. Xiao Z., et al. Engineering of targeted nanoparticles for cancer therapy using internalizing aptamers isolated by cell-uptake selection. ACS Nano 2012, 6(1):696-704.
129. Delehanty J., Mattoussi H., Medintz I. Delivering quantum dots into cells: strategies, progress and remaining issues. Anal. Bioanal. Chem. 2009, 393(4):1091-1105.
130. Chen B., et al. Transmembrane delivery of the cell-penetrating peptide conjugated semiconductor quantum dots. Langmuir 2008, 24(20):11866-11871.
131. Ruan G., et al. Imaging and tracking of Tat peptide-conjugated quantum dots in living cells: new insights into nanoparticle uptake, intracellular transport, and vesicle shedding. J. Am. Chem. Soc. 2007, 129(47):14759-14766.
132. Anas A., et al. Clathrin-mediated endocytosis of quantum dot-peptide conjugates in living cells. ACS Nano 2009, 3(8):2419-2429.
133. Duan H., Nie S. Cell-penetrating quantum dots based on multivalent and endosome-disrupting surface coatings. J. Am. Chem. Soc. 2007, 129(11):3333-3338.
134. Yezhelyev M.V., et al. Proton-sponge coated quantum dots for siRNA delivery and intracellular imaging. J. Am. Chem. Soc. 2008, 130(28):9006-9012.
135. Li S.D., Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 2008, 5(4):496-504.
136. Cai W., et al. Peptide-labeled near-infrared quantum dots for imaging tumor vasculature in living subjects. Nano Lett. 2006, 6(4):669-676.
137. Bakalova R., et al. Chemical nature and structure of organic coating of quantum dots is crucial for their application in imaging diagnostics. Int. J. Nanomed. 2011, 6:1719-1732.
138. Jung K.H., et al. 99mTc-Hydrazinonicotinamide epidermal growth factor-polyethylene glycol-quantum dot imaging allows quantification of breast cancer epidermal growth factor receptor expression and monitors receptor downregulation in response to cetuximab therapy. J. Nucl. Med. 2011, 52(9):1457-1464.
139. Duconge F., et al. Fluorine-18-labeled phospholipid quantum dot micelles for in vivo multimodal imaging from whole body to cellular scales. Bioconjug. Chem. 2008, 19(9):1921-1926.
140. Ballou B., et al. Noninvasive imaging of quantum dots in mice. Bioconjug. Chem. 2004, 15(1):79-86.
141. Choi H.S., et al. Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano Lett. 2009, 9(6):2354-2359.
142. Daou T.J., et al. Effect of poly(ethylene glycol) length on the in vivo behavior of coated quantum dots. Langmuir 2009, 25(5):3040-3044.
143. Akerman M.E., et al. Nanocrystal targeting in vivo. Proc. Natl. Acad. Sci. U. S. A. 2002, 99(20):12617-12621.
144. Bhirde A.A., et al. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano 2009, 3(2):307-316.
145. Diagaradjane P., et al. Imaging epidermal growth factor receptor expression in vivo: pharmacokinetic and biodistribution characterization of a bioconjugated quantum dot nanoprobe. Clin. Cancer Res. 2008, 14(3):731-741.
146. Kim K.S., et al. Bioimaging for targeted delivery of hyaluronic Acid derivatives to the livers in cirrhotic mice using quantum dots. ACS Nano 2010, 4(6):3005-3014.
147. Gao X., et al. Quantum dots bearing lectin-functionalized nanoparticles as a platform for in vivo brain imaging. Bioconjug. Chem. 2008, 19(11):2189-2195.
148. Tada H., et al. In vivo real-time tracking of single quantum dots conjugated with monoclonal anti-HER2 antibody in tumors of mice. Cancer Res. 2007, 67(3):1138-1144.
149. Danhier F., et al. Paclitaxel-loaded PEGylated PLGA-based nanoparticles: in vitro and in vivo evaluation. J. Control. Release 2009, 133(1):11-17.
150. Liu S., et al. Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 2008, 111(4):2364-2373.
151. Liu Y., et al. Multifunctional silica nanoparticles for targeted delivery of hydrophobic imaging and therapeutic agents. Int. J. Pharm. 2011, 421(2):370-378.
152. Malam Y., Loizidou M., Seifalian A.M. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol. Sci. 2009, 30(11):592-599.
153. Bagalkot V., et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett. 2007, 7(10):3065-3070.
154. Savla R., et al. Tumor targeted quantum dot-mucin 1 aptamer-doxorubicin conjugate for imaging and treatment of cancer. J. Control. Release. 2011, 153(1):16-22.
155. Oh Y.-K., Park T.G. siRNA delivery systems for cancer treatment. Adv. Drug Delivery Rev. 2009, 61(10):850-862.
156. Mark E.D. Non-viral gene delivery systems. Curr. Opin. Biotechnol. 2002, 13(2):128-131.
157. Singh N., et al. Effect of nanoparticle conjugation on gene silencing by RNA interference. J. Am. Chem. Soc. 2010, 132(24):8241-8243.
158. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 2009, 8(2):129-138.
159. Derfus A.M., et al. Targeted quantum dot conjugates for siRNA delivery. Bioconjug. Chem. 2007, 18(5):1391-1396.
160. Bagalkot V., Gao X. siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing. ACS Nano 2011, 5(10):8131-8139.
161. Jung J., et al. Selective inhibition of human brain tumor cells through multifunctional quantum-dot-based siRNA delivery. Angew. Chem. 2009, 122(1):107-111.
162. Zhao M.-X., et al. Targeted cellular uptake and siRNA silencing by quantum-dot nanoparticles coated with β-cyclodextrin coupled to amino acids. Chem. Eur. J. 2011, 17(18):5171-5179.
163. Medarova Z., et al. In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med. 2007, 13(3):372-377.
164. Paolino D., et al. Gemcitabine-loaded PEGylated unilamellar liposomes vs GEMZAR®: biodistribution, pharmacokinetic features and in vivo antitumor activity. J. Control. Release 2009, 144(2):144-150.
165. Weissleder R., Pittet M.J. Imaging in the era of molecular oncology. Nature 2008, 452(7187):580-589.
166. Love K.T., et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl. Acad. Sci. 2009, 107(5):1864-1869.
167. Zolnik B.S., et al. Minireview: nanoparticles and the immune system. Endocrinology 2010, 151(2):458-465.
168. Bastus N.G., et al. Peptides conjugated to gold nanoparticles induce macrophage activation. Mol. Immunol. 2009, 46(4):743-748.
169. Chakravarthy K.V., et al. Gold nanorod delivery of an ssRNA immune activator inhibits pandemic H1N1 influenza viral replication. Proc. Natl. Acad. Sci. 2010, 107(22):10172-10177.
170. Peek L.J., Middaugh C.R., Berkland C. Nanotechnology in vaccine delivery. Adv. Drug Delivery Rev. 2008, 60(8):915-928.
171. Bordon Y. Therapeutic cancer vaccine approved. Nat. Rev. Immunol. 2010, 10(6). 380-380.
172. Lipson E.J., Drake C.G. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin. Cancer Res. 2011, 17(22):6958-6962.
173. Cho N.-H., et al. A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. Nat. Nanotechnol. 2011, 6(10):675-682.
174. Mellman I., Coukos G., Dranoff G. Cancer immunotherapy comes of age. Nature 2011, 480(7378):480-489.
175. Goldman B., DeFrancesco L. The cancer vaccine roller coaster. Nat. Biotechnol. 2009, 27(2):129-139.
176. Noh Y.-W., et al. Simultaneous in vivo tracking of dendritic cells and priming of an antigen-specific immune response. Biomaterials 2011, 32(26):6254-6263.
177. Dudziak D., et al. Differential antigen processing by dendritic cell subsets in vivo. Science 2007, 315(5808):107-111.
178. Mackay P.S., et al. Multimodal imaging of dendritic cells using a novel hybrid magneto-optical nanoprobe. Nanomedicine 2011, 7(4):489-496.
179. Sen D., et al. Quantum dots for tracking dendritic cells and priming an immune response in vitro and in vivo. PLoS One 2008, 3(9):e3290.
180. Delehanty J.B., et al. Delivering quantum dot-peptide bioconjugates to the cellular cytosol: escaping from the endolysosomal system. Integr. Biol. (Camb.) 2010, 2(5-6):265-277.